Study S002555

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 in Adult Chinese Patients With Obesity or Overweight, With or Without Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT07670416
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: RECRUITING
Enrollment: 300
Start: 2026-07-03
Primary completion: 2028-02-24
Lead sponsor: Hoffmann-La Roche
Conditions: Obesity; Overweight; Type 2 Diabetes Mellitus (T2DM)
Interventions: COMBINATION_PRODUCT:Enicepatide; COMBINATION_PRODUCT:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Percent Change From Baseline in Body Weight at Week 52 [Baseline through Week 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.